Grifois, S.A. - GRFS STOCK NEWS

Grifols has launched its new ALBUTEIN FlexBag™, offering albumin in 5% and 25% concentrations, catering specifically to U.S. hospitals and pharmacies. This innovation features an easy-to-use port, minimizing bubble accumulation and needle stick risks. The FDA approved the 5% and 25% concentrations earlier in 2021, with a focus on sustainability, reducing the carbon footprint by 40% during manufacturing. This launch underscores Grifols' commitment to research and innovation, expanding its plasma-derived medicine portfolio to enhance patient care.

Grifols has launched HyperHEP B, a new formulation of hepatitis B immune globulin, approved by the FDA in December 2020, specifically for postexposure prophylaxis against hepatitis B. The product, utilizing a unique purification process, aims to enhance safety standards and reduce procoagulant activity. HyperHEP B is expected to serve approximately 800,000 to 1.4 million infected individuals in the U.S., with three different presentation sizes available. Grifols' ongoing commitment includes donating six million international units to underserved countries.

Grifols has announced the opening of the first AMBAR® Center in Barcelona, collaborating with Ace Alzheimer Center Barcelona. This center aims to collect real-world data from the AMBAR® clinical program, which uses periodic plasma exchange to slow cognitive and functional decline in Alzheimer's patients. The partnership aims to enhance the treatment and management of Alzheimer's with plans for future centers in the EU, U.S., and China. Over 35 million people globally suffer from Alzheimer's, emphasizing the significance of this innovation.

Grifols has partnered with the government of Andorra to create the Pyrenees Immunology Research Center (PYIRC), a modern facility aimed at advancing immunology research and therapy development. The center, set to open in 2023, will focus on immune system disorders, such as autoimmunity and cancer, and will attract international experts. Grifols will own 80% of the joint venture and invest approximately €25 million in construction, with €7 million in annual operating costs. This initiative aligns with Andorra's economic diversification goals in biotechnology and innovation.

Grifols announced a donation of 240 million international units of blood clotting factor medicines to the World Federation of Hemophilia from 2022 to 2030, bringing total contributions to over 440 million IU since 2014. This support aims to treat approximately 3,000 patients annually in developing countries, addressing global health inequities. Grifols' commitment reinforces its dedication to the hemophilia community and aligns with its mission to improve health access globally.

Grifols, S.A. (NASDAQ: GRFS), announced the filing of its 2020 Annual Report on Form 20-F with the SEC on April 9, 2021. This report includes audited financial statements for the fiscal year that ended on December 31, 2020. The Form 20-F can be accessed on both Grifols' website and the SEC's site. Shareholders can request a hard copy of the report, free of charge. Grifols is a global healthcare company focused on innovative solutions across its four divisions: Bioscience, Diagnostic, Hospital, and Bio Supplies, impacting the economy with EUR 7.5 billion and creating 140,000 jobs in 2020.

Grifols announced that its Phase 3 ITAC clinical trial for anti-coronavirus immunoglobulin did not achieve its primary endpoints. Despite this setback, the company is pursuing over 20 ongoing research efforts to identify COVID-19 treatment options. Grifols will collaborate on international studies involving intravenous and subcutaneous hyperimmune globulins for COVID-19 patients, along with evaluating other plasma-derived treatments. The trial enrolled nearly 600 patients across multiple countries, but the failure to meet primary endpoints raises concerns about the efficacy of the treatment.

Grifols (NASDAQ: GRFS) has announced the installation of its DG Reader Net semi-automated analyzer at ThedaCare Medical Center-Wild Rose in Wisconsin, marking its first in North America. This advanced system enhances pre-transfusion blood type compatibility testing by automating the reading of DG Gel cards, significantly reducing manual errors. The implementation will enable quicker results, crucial for timely blood transfusions in critical care settings. Grifols aims to improve patient safety and efficiency in laboratories, reinforcing its commitment to innovative diagnostic solutions.

Grifols has installed its first DG Reader Net semi-automated analyzer in North America at ThedaCare Medical Center-Wild Rose, Wisconsin. This innovative platform automates blood type compatibility testing, offering improved efficiency by providing results in minutes, crucial for critical care environments. The system minimizes manual errors by uploading results directly to the Laboratory Information System, enhancing patient safety. With a growing network of donation centers and a strong presence in the healthcare sector, Grifols continues to innovate in diagnostic solutions to improve healthcare delivery.